Amgen Inc. $AMGN Shares Purchased by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP increased its position in Amgen Inc. (NASDAQ:AMGN) by 65.5% in the third quarter, HoldingsChannel reports. The firm owned 4,428 shares of the medical research company’s stock after purchasing an additional 1,752 shares during the quarter. Fulcrum Asset Management LLP’s holdings in Amgen were worth $1,876,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Wellington Altus USA Inc. raised its holdings in Amgen by 72.3% in the second quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock worth $28,000 after purchasing an additional 34 shares in the last quarter. Quest 10 Wealth Builders Inc. grew its position in shares of Amgen by 220.0% in the 3rd quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company’s stock worth $34,000 after buying an additional 55 shares during the period. Nvwm LLC grew its position in shares of Amgen by 412.5% in the 3rd quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock worth $35,000 after buying an additional 66 shares during the period. Security National Bank of Sioux City Iowa IA purchased a new stake in shares of Amgen in the 2nd quarter worth about $36,000. Finally, PFS Partners LLC increased its stake in shares of Amgen by 95.5% in the 3rd quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock worth $36,000 after acquiring an additional 42 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Performance

Shares of AMGN opened at $465.23 on Wednesday. The company has a market cap of $251.65 billion, a price-to-earnings ratio of 26.99, a P/E/G ratio of 3.25 and a beta of 0.43. The business’s fifty day simple moving average is $423.79 and its two-hundred day simple moving average is $379.39. Amgen Inc. has a 12 month low of $312.39 and a 12 month high of $483.99. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, topping the consensus estimate of $5.79 by $0.66. The firm had revenue of $10.37 billion during the quarter, compared to analysts’ expectations of $10.07 billion. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The company’s revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.64 earnings per share. Research analysts anticipate that Amgen Inc. will post 23.33 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be given a $2.52 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a yield of 2.2%. Amgen’s payout ratio is 58.47%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New data presented at the American Heart Association’s 2026 Scientific Sessions strengthened the case for earlier and more intensive Repatha treatment. Amgen cited an analysis finding the drug highly cost-effective in high-risk patients without a prior heart attack or stroke, and a long-term analysis associating it with a 29% lower risk of major cardiovascular events in patients with existing cardiovascular disease. These findings could support Repatha’s clinical profile and adoption, although the reported evidence includes an external-control analysis. Read article
• Neutral Sentiment: Investors are watching for ACR conference data on dazodalibep. The coverage frames the results as a test for the program, but the provided reports do not disclose findings, so the clinical and stock impact remains uncertain. Read article
• Neutral Sentiment: Recent coverage also compares Amgen’s dividend income and valuation with Regeneron’s faster growth, while another report says analyst views on Amgen are mixed. Neither item provides a specific new forecast or rating change that clearly shifts the near-term outlook. Read article

Insiders Place Their Bets

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Leerink Partners lifted their price target on shares of Amgen from $395.00 to $464.00 and gave the company a “market perform” rating in a research report on Thursday, November 5th. Jefferies Financial Group restated a “hold” rating and issued a $410.00 price objective on shares of Amgen in a report on Wednesday, September 23rd. Bank of America raised their target price on shares of Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research note on Wednesday, August 5th. Robert W. Baird raised their target price on shares of Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research note on Wednesday, August 5th. Finally, BMO Capital Markets lowered their target price on shares of Amgen from $450.00 to $415.00 and set a “market perform” rating for the company in a report on Monday, October 12th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Amgen currently has a consensus rating of “Hold” and an average target price of $422.76.

Amgen Company Profile

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.